ArticleNeuro-oncology2013
Impact of MACC1 on human malignant glioma progression and patients' unfavorable prognosis.
Article in Neuro-oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.
- MACC1 overexpression and survival in solid tumors: a meta-analysis.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Pooled it
- Clinical relevance of circulating MACC1 and S100A4 transcripts for ovarian cancer.Molecular oncology · 2019Trial
- MACC1 revisited - an in-depth review of a master of metastasis.Biomarker research · 2024Review
- Article
- BRMS1 in Gliomas-An Expression Analysis.Cancers · 2023Article
- MACC1-induced migration in tumors: Current state and perspective.Frontiers in oncology · 2023Review
- MACC1 promotes pancreatic cancer metastasis by interacting with the EMT regulator SNAI1.Cell death & disease · 2022Article
- MACC1-Induced Collective Migration Is Promoted by Proliferation Rather Than Single Cell Biomechanics.Cancers · 2022Article
- IFN-γ affects pancreatic cancer properties by MACC1-AS1/MACC1 axis via AKT/mTOR signaling pathway.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022Article
- MACC1 Promotes the Progression and Is a Novel Biomarker for Predicting Immunotherapy Response in Colorectal Cancer.Journal of oncology · 2022Article
- Article
- Norepinephrine inhibits migration and invasion of human glioblastoma cell cultures possibly via MMP-11 inhibition.Brain research · 2021Article
- Close interactions between lncRNAs, lipid metabolism and ferroptosis in cancer.International journal of biological sciences · 2021Review
- Preparation and Culture of Organotypic Hippocampal Slices for the Analysis of Brain Metastasis and Primary Brain Tumor Growth.Methods in molecular biology (Clifton, N.J.) · 2021Article
- MACC1 driven alterations in cellular biomechanics facilitate cell motility in glioblastoma.Cell communication and signaling : CCS · 2020Article
- Circulating MACC1 Transcripts in Glioblastoma Patients Predict Prognosis and Treatment Response.Cancers · 2019Article
- Synthetic Cannabinoids Influence the Invasion of Glioblastoma Cell Lines in a Cell- and Receptor-Dependent Manner.Cancers · 2019Article
- Opposite Effects of Neuroprotective Cannabinoids, Palmitoylethanolamide, and 2-Arachidonoylglycerol on Function and Morphology of Microglia.Frontiers in neuroscience · 2019Article
- Prognostic and Risk Stratification Value of Lesion MACC1 Expression in Colorectal Cancer Patients.Frontiers in oncology · 2019Article
- MicroRNA-598 Inhibits Cell Proliferation and Invasion of Glioblastoma by Directly Targeting Metastasis Associated in Colon Cancer-1 (MACC1).Oncology research · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMetastasis-associated in colon cancer 1 (MACC1) has been established as an independent prognostic indicator of metastasis formation and metastasis-free survival for patients with colon cancer and other solid tumors. However, no data are available concerning MACC1 expression in human astrocytic tumors. Glioblastoma multiforme (GBM) is the most prevalent primary brain tumor of adulthood, and due to its invasive and rapid growth, patients have unfavorable prognoses. Although these tumors rarely metastasize, their invasive and migratory behavior is similar to those of metastatic cells of tumors of different origin. Thus, we hypothesized that MACC1 may be involved in progression of human gliomas.
methodsWe performed real-time measurements of proliferation and migration in MACC1-transfected GBM cell lines (U138, U251) and evaluated tumor formation in organotypic hippocampal slice cultures of mice. Semiquantitative and quantitative real-time reverse transcription PCR analyses were performed for MACC1 and for its transcriptional target c-Met in human astrocytoma of World Health Organization grade II (low-grade astrocytoma) and GBM biopsies. Data were validated by MACC1 immunohistochemistry in independent matched samples of low-grade astrocytoma and GBM.
resultsMACC1 increases the proliferative, migratory, and tumor-formation abilities of GBM cells. The c-Met inhibitor crizotinib reduced MACC1-induced migration and tumor formation in organotypic hippocampal slice cultures of mice. Analyzing patients' biopsies, MACC1 expression increased concomitantly with increasing World Health Organization grade. Moreover, MACC1 expression levels allowed discrimination of dormant and recurrent low-grade astrocytomas and of primary and secondary GBM. Strong MACC1 expression correlated with reduced patient survival.
conclusionsMACC1 may represent a promising biomarker for prognostication and a new target for treatment of human gliomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.